Inspire Beats Q2 Estimates Despite 7.6% Revenue Dip, Raises Full-Year Guidance

Medical device maker Inspire Medical Systems (INSP) reported fiscal Q2 2026 results after the close on August 3, beating Wall Street estimates on both revenue and profit while raising its full-year outlook. According to StockStory, shares jumped as much as 13.6% following the release.^{[FinancialContent]} With U.S. markets closed for the holiday, there was no live trading; as of the August 3, 2026 close, Inspire Medical Systems (INSP) shares were at $1,121.36, down 2.39% ($27.48) from the prior session's close of $1,148.84. The stock opened at $1,152, traded as high as $1,161.94 and as low as $1,109.15 during the session. Quotes remained at the prior close during the market holiday, with no pre-market or intraday movement.

Revenue Beats Despite Decline, Earnings Turn Sharply Positive

Inspire Medical Systems posted Q2 revenue of $200.6 million, down 7.6% year over year but 3% above the $194.7 million analysts had forecast.^{[FinancialContent]} Over a longer horizon, the company's revenue has compounded at 38.7% annually over the past five years, outpacing the typical healthcare company; over the last two years, annualized revenue growth was 12.9%.^{[FinancialContent]}

On the bottom line, adjusted EPS came in at $0.14, well ahead of the $0.25 per-share loss analysts expected. Adjusted EBITDA was $38.9 million, a 19.4% margin and 40.5% above the $27.68 million consensus.^{[FinancialContent]} That said, operating margin came in at -0.3%, down from 4.4% in the year-ago period.^{[FinancialContent]}

Guidance Raised, CEO Cites Coding and Reimbursement Navigation

Management nudged up its full-year revenue guidance, lifting the midpoint to $855 million from $850 million, 1.4% above analyst expectations. The company also raised its full-year adjusted EPS guidance midpoint to $1.25, a 25% increase.^{[FinancialContent]}

Chairman and CEO Tim Herbert said in the release: "Our second quarter results reflect the increased discipline and focus we are bringing to the business as we continue to support our customers in a changing coding and reimbursement environment and invest in the long-term adoption of Inspire therapy."^{[FinancialContent]}

Company Background and Business Overview

Inspire Medical Systems is a medical technology company focused on developing and selling implantable neurostimulation devices to treat obstructive sleep apnea (OSA). Its flagship Inspire system stimulates the hypoglossal nerve to keep the airway open during sleep, offering an alternative for patients who cannot tolerate or are poorly managed on continuous positive airway pressure (CPAP) devices. The system consists of an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve. The device received FDA approval in 2014 and later earned CE marking for sale in Europe.^[MarketBeat]

Founded in 2007 and headquartered in Golden Valley, Minnesota, the company operates across North America and Europe, with continued expansion into select international markets. The company is led by President and CEO Michael A. Moulder.^[MarketBeat] Notably, per MarketBeat, the company currently lists Tim Herbert as Chairman and CEO alongside Michael A. Moulder as President and CEO, with both roles on record.^[MarketBeat]

Stock Performance and Market Valuation

As of the August 3, 2026 close, Inspire Medical Systems had a market cap of roughly $1.45 billion.^{[FinancialContent]} Simply Wall St data shows a market cap of about $1.5 billion, with the stock down 59.4% over the past year, up 6.8% over the last seven days, and down 1.5% in the prior session.^{[Simply Wall St]}

Simply Wall St's analysis notes the stock trades 5.9% below its fair value estimate, with earnings up 97.2% over the past year, and valuation looking reasonable versus peers and the broader industry. On the risk side, however, analysts project earnings to decline an average of 15.4% annually over the next three years.^{[Simply Wall St]} On Simply Wall St's scoring system, the company rates 4/6 for valuation, 0/6 for future growth, 5/6 for past performance, 6/6 for financial health, and 0/6 for dividends.^{[Simply Wall St]}

This content is for informational purposes only and does not constitute investment advice, trading advice, or any guarantee of returns.